My reaction is that you are not being realistic. Roskamp has done three mouse studies, peer reviewed and published, in which the peer reviewers, apparently impressed with the results, recommended additional studies.
The reaction by other medical researchers? ZILCH! No one believes it! Not even the support groups for AD, Hashimoto's Thyroiditis, or Multiple Sclerosis, which were the object of the three studies.
Again, some success with Nilvad and AD, may lead to the recognition that Anatabine desperately needs.
News 
Market Data 
Discover 
